IONS241220C22500
- 0.00
- 0.000.00%
Ionis Pharmaceuticals Newsroom
J.P. Morgan Maintains Ionis Pharmaceuticals(IONS.US) With Hold Rating, Cuts Target Price to $51
Analysts Conflicted on These Healthcare Names: Ionis Pharmaceuticals (IONS) and GoodRx Holdings (GDRX)
Ionis Pharmaceuticals (IONS) Upgraded to Buy: What Does It Mean for the Stock?
Praxis Precision Medicines to Showcase Updates From Largest Epilepsy Pipeline of Precision Epilepsy Programs at the 2024 American Epilepsy Society Annual Meeting
Pfizer Meets Amyloidosis Rival as BridgeBio Wins FDA Nod for Attruby
Ionis Pharmaceuticals, Inc. (IONS): Among the Best Genomics Stocks to Buy Right Now
Here's Why Ionis Pharmaceuticals (IONS) Is Poised for a Turnaround After Losing -13.46% in 4 Weeks
Express News | Shares of Pharmaceutical and Healthcare Stocks Are Trading Lower. The Sector Has Been Under Pressure After President-elect Trump Nominated Robert F. Kennedy Jr. to Lead the HHS
Catalyst Watch: Nvidia Earnings, Microsoft Ignite, Crypto Confidence, and P&G Event
Ionis Pharmaceuticals Is Maintained at Overweight by Piper Sandler
Flamingo Therapeutics Announces Oral Presentation at AACR Special Conference in Cancer Research on RNAs as Drivers, Targets, and Therapeutics in Cancer
Piper Sandler Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Cuts Target Price to $62
10 Health Care Stocks Whale Activity In Today's Session
Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Shares Lagging The Industry But So Is The Business
A Quick Look at Today's Ratings for Ionis Pharmaceuticals(IONS.US), With a Forecast Between $45 to $77
Ionis Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations
Ionis Pharmaceuticals: Promising Pipeline and Strategic Milestones Drive Buy Rating
Where Ionis Pharmaceuticals Stands With Analysts
A Quick Look at Today's Ratings for Ionis Pharmaceuticals(IONS.US), With a Forecast Between $51 to $77
Ionis to Present at Upcoming Investor Conferences